ARA 290 Research Peptide Overview
ARA 290 (also known as Cibinetide) is a synthetic 11-amino acid peptide derived from the helix B domain of erythropoietin, engineered as a selective agonist of the innate repair receptor for investigation in preclinical models of tissue protection and inflammatory signaling.
Molecular Composition and Mechanistic Profile
Peptide identity: ARA 290 is a linear non-erythropoietic peptide modeled on the tissue protective region of erythropoietin.
Origin: Designed from the three-dimensional structure of EPO helix B to engage the innate repair receptor while avoiding hematopoietic activity.
Mechanistically, ARA 290 has been associated with:
Selective binding to the innate repair receptor, a heteromeric complex of the erythropoietin receptor and the β-common receptor (CD131).
Activation of downstream anti-inflammatory and cytoprotective pathways that limit tissue injury signals in experimental systems.
Support of repair oriented signaling in neural, vascular, and immune cell preparations without stimulating red blood cell production.
These properties position ARA 290 as a tool for studying receptor-selective tissue protection mechanisms.
Integrated Research Applications
ARA 290 is examined across systems involving inflammation and tissue resilience. Representative domains include:
Neuroprotection and neuropathy models: Investigation of small fiber and peripheral nerve responses, inflammatory modulation, and structural markers in rodent injury preparations.
Inflammatory and tissue injury models: Evaluation of anti-inflammatory signaling and cytoprotection under experimental stress or damage conditions.
Innate repair receptor research: Use as a selective probe to explore IRR-mediated pathways distinct from classical erythropoietin receptor activity.
Comparative EPO-analog studies: Assessment of non-hematopoietic tissue-protective effects relative to full-length erythropoietin in controlled laboratory settings.
Overall, ARA 290 serves as a research tool for exploring selective innate repair receptor activation and its role in coordinated tissue protection.
Analytical Validation, Formulation, and Storage
NextGenPeps supplies ARA 290 as a high-purity research peptide. Typical quality and handling features include:
Purity: ≥99% verified by HPLC.
Formulation: White lyophilized powder in sealed glass vials, intended for reconstitution with appropriate research-grade solvent for experimental use only. No dosing guidance is provided for any organism.
Storage: Keep lyophilized material in a cool, dark, dry environment; long-term storage at or below −20 °C. Store reconstituted solutions refrigerated, minimize freeze-thaw cycles, and use within laboratory-defined stability windows.
These conditions support structural integrity and reproducible experimental outcomes.
NextGenPeps supplies ARA 290 as a high-purity research peptide intended strictly for controlled laboratory use in vitro or in established animal models, such as murine systems. This compound is not approved as a drug, diagnostic, or dietary ingredient, and is not manufactured, packaged, or marketed for human consumption, self-experimentation, clinical application, or any use outside properly designed and ethically approved research protocols.
